Vancouver, BC / ACCESSWIRE / June 6, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on North American medicinal markets, today announced that they will be presenting at the WeedStock conference presented by Marketfy. The conference will feature a robust lineup of the cannabis industry's foremost experts. Despite recent challenges facing the industry and its investors, widespread support of legalization across the country suggests that the cannabis industry is a viable long-term industry for investors.
Marketfy is proud to announce a diverse lineup of carefully selected companies to deliver defining presentations, some of which include:
-
--Abattis Bioceuticals (OTC: ATTBF)
-
--Advanced Cannabis Solutions (OTC: CANN)
-
--WeedHire.com (OTC: ANYI)
-
--Cannabis Technologies (OTC: CANLF)
-
--Endexx Corporation (OTC: EDXC)
-
--Agritek Holdings (OTC: MWIP)
-
--Tauriga Sciences Inc (OTC: TAUG)
-
--MassRoots
-
--...and many more!
The conference will feature panel discussions, one-on-one meetings and networking opportunities like a VIP cocktail reception. Internationally acclaimed cannabis investors, such as Alan Brochstein of the 420 Investor and Rod David of the Marijuana Stock Technical Trader, will also be discussing their strategies for the space.
The three-day conference will take place from June 29th through July 1st at the Westin Denver Downtown in Denver, Colorado. To learn more about the WeedStock conference and purchase your tickets before they are sold out, visit http://www.weedstockconference.com/. The first 10 people to use the promotion code "WEEDSTOCKPR" will receive a $199 discount on any three-day pass packages.
CEO Mike Withrow commented, "We are pleased to be at WeedStock in July. We invite everyone to come and learn more about Abattis and the companies we have invested in, which include mass vertical cultivation technologies, proprietary extraction technologies, Phytalab.com and Instant Payment Systems LLC. We are looking forward to meeting with prospective strategic partners who are interested in utilizing our company technologies in the states they reside in."
About the WeedStock Conference
The three-day conference will include exhibits and presentations by privately held and publicly traded companies in the cannabis industry, industry keynote speakers, panel discussions, one-on-one meetings and networking events. Opportunities, challenges and regulation in the space are among the topics to be discussed. The Weedstock Conference will take place from June 29 through July 1 at the Westin Denver Downtown in Denver, Colorado. To learn more about the WeedStock conference, visit www.weedstockconference.com
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law's of Canada and Foreign Jurisdictions. For more information, visit the Company's website at www.abattis.com.
ON BEHALF OF THE BOARD
"Mike Withrow"
Michael Withrow
President & CEO
For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at [email protected].
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
SOURCE: Abattis Bioceuticals Corp.